CARsgen Initiates Trial For KJ-C2219, An Allogeneic CAR T Therapy

CARsgen Therapeutics Holdings Limited is a clinical-stage biotechnology company developing transgenic CAR T-cell therapies for hematologic malignancies and solid tumours. The Company reported that it has launched an investigator-initiated trial (IIT) in China for KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20. 

The trial will assess KJ-C2219 for relapsed/refractory B-cell non-Hodgkin lymphoma, also known as R/R B-NHL. KJ-C2219 is created using THANK-u Plus, CARsgen’s proprietary platform, and the company’s second-generation treatment is anticipated to be used in the treatment of hematologic malignancies and autoimmune diseases.